End-of-day quote
Shenzhen S.E.
18:00:00 2024-05-13 EDT
|
5-day change
|
1st Jan Change
|
35.63
CNY
|
-0.78%
|
|
-1.93%
|
+23.03%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
6,210
|
5,481
|
7,138
|
10,662
|
6,786
|
8,349
|
-
|
-
|
Enterprise Value (EV)
1 |
6,210
|
5,481
|
7,138
|
10,662
|
6,786
|
8,349
|
8,349
|
8,349
|
P/E ratio
|
30.5
x
|
18.7
x
|
18.8
x
|
20.2
x
|
11.6
x
|
12.5
x
|
11
x
|
9.68
x
|
Yield
|
1.13%
|
1.5%
|
2.63%
|
-
|
6.91%
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.45
x
|
3.01
x
|
3.52
x
|
4.55
x
|
2.73
x
|
2.97
x
|
2.63
x
|
2.35
x
|
EV / Revenue
|
3.45
x
|
3.01
x
|
3.52
x
|
4.55
x
|
2.73
x
|
2.97
x
|
2.63
x
|
2.35
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
3.59
x
|
2.8
x
|
3.26
x
|
4.13
x
|
2.28
x
|
2.62
x
|
2.45
x
|
2.28
x
|
Nbr of stocks (in thousands)
|
234,331
|
234,331
|
234,331
|
234,331
|
234,331
|
234,331
|
-
|
-
|
Reference price
2 |
26.50
|
23.39
|
30.46
|
45.50
|
28.96
|
35.63
|
35.63
|
35.63
|
Announcement Date
|
20-03-06
|
21-01-15
|
22-01-18
|
23-01-19
|
24-01-20
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,800
|
1,820
|
2,027
|
2,341
|
2,484
|
2,809
|
3,169
|
3,556
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
414.2
|
612.7
|
818.1
|
1,160
|
1,326
|
1,520
|
1,728
|
1,952
|
Operating Margin
|
23.01%
|
33.67%
|
40.36%
|
49.56%
|
53.37%
|
54.11%
|
54.53%
|
54.89%
|
Earnings before Tax (EBT)
1 |
414.4
|
619.7
|
821.1
|
1,159
|
1,325
|
1,519
|
1,727
|
1,951
|
Net income
1 |
204.1
|
292.3
|
380.3
|
526.9
|
585.3
|
671
|
763
|
862
|
Net margin
|
11.34%
|
16.06%
|
18.76%
|
22.51%
|
23.56%
|
23.89%
|
24.08%
|
24.24%
|
EPS
2 |
0.8700
|
1.250
|
1.620
|
2.250
|
2.500
|
2.860
|
3.250
|
3.680
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
0.3000
|
0.3500
|
0.8000
|
-
|
2.000
|
-
|
-
|
-
|
Announcement Date
|
20-03-06
|
21-01-15
|
22-01-18
|
23-01-19
|
24-01-20
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
12.3%
|
15.9%
|
18.1%
|
22.1%
|
21.1%
|
21.1%
|
22.4%
|
23.5%
|
ROA (Net income/ Total Assets)
|
6.75%
|
8.49%
|
9.98%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
3,026
|
3,442
|
3,810
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
7.390
|
8.340
|
9.340
|
11.00
|
12.70
|
13.60
|
14.60
|
15.60
|
Cash Flow per Share
2 |
1.040
|
3.140
|
2.710
|
5.110
|
5.010
|
5.380
|
6.160
|
6.900
|
Capex
|
172
|
-
|
120
|
-
|
48.7
|
-
|
-
|
-
|
Capex / Sales
|
9.58%
|
-
|
5.93%
|
-
|
1.96%
|
-
|
-
|
-
|
Announcement Date
|
20-03-06
|
21-01-15
|
22-01-18
|
23-01-19
|
24-01-20
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +23.03% | 1.16B | | +31.06% | 682B | | +30.35% | 586B | | -3.42% | 364B | | +18.02% | 327B | | +4.27% | 285B | | +15.53% | 240B | | +10.16% | 209B | | -8.14% | 203B | | +8.12% | 165B |
Other Pharmaceuticals
|